©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Systematic Mutational Analysis of the Death Domain of the Tumor Necrosis Factor Receptor 1-associated Protein TRADD (*)

(Received for publication, November 21, 1995; and in revised form, January 16, 1996)

Adam Park Vijay R. Baichwal

From the From Tularik Inc., South San Francisco, California 94080

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Tumor necrosis factor receptor 1 (TNF-R1) mediates most of the biological properties of TNF including activation of the transcription factor NF-kappaB and programmed cell death. An 80-amino acid region within the intracellular domain of the receptor, termed the death domain, is required for signaling NF-kappaB activation and cytotoxicity. A TNF-R1-associated protein TRADD has been discovered that interacts with the death domain of the receptor. Elevated expression of TRADD in cells triggers both NF-kappaB activation and programmed cell death pathways. The biological activities of TRADD have been mapped to a 111-amino acid region within the carboxyl-terminal half of the protein. This region shows sequence similarity to the death domain of TNF-R1 and can self-associate and bind to the TNF-R1 death domain. We have performed an alanine scanning mutagenesis of TRADD's death domain to explore the relationship among its various functional properties. Mutations affecting the different activities of TRADD do not map to discrete regions but rather are spread over the entire death domain, suggesting that the death domain is a multifunctional unit. A mutant that separates cell killing from NF-kappaB activation by the TRADD death domain has been identified indicating that these two signaling pathways diverge with TRADD. Additionally, one of the TRADD mutants that fails to activate NF-kappaB was found to act as dominant negative mutant capable of preventing induction of NF-kappaB by TNFalpha. Such observations provide evidence that TRADD performs an obligate role in TNF-induced NF-kappaB activation.


INTRODUCTION

Tumor necrosis factor alpha (TNFalpha) (^1)is a pro-inflammatory cytokine that performs varied biological functions including antiviral activity, cytotoxicity, and reprogramming of gene expression (reviewed in (1, 2, 3) ). The different effects of TNFalpha are elicited by binding to two distinct cell surface receptors: TNF receptor 1 (TNF-R1, 55 kDa) and TNF receptor 2 (TNF-R2, 75 kDa). Although most cell types express both TNF receptors, TNF-R1 appears to be primarily responsible for induction of gene expression and programmed cell death by TNFalpha (reviewed in (4) and (5) ). Binding of the trimeric TNFalpha ligand to the receptor results in receptor aggregation, which is thought to be a critical event triggering downstream signaling pathways either by activating receptor-associated effector molecules or by recruiting effector molecules(6, 7) . Several signal transduction pathways and signaling molecules have been associated with TNFalpha action including generation of oxygen radicals and activation of protein kinases and sphingomyelinases (reviewed in (8) ). However, it is not clear if these events reflect primary cellular changes in response to receptor occupancy or secondary events that are a consequence of other more immediate postreceptor activation steps triggered by TNFalpha.

Analysis of the regulation of gene expression by TNF has revealed binding sites for the transcription factor NF-kappaB in the promoter region of most genes induced by TNF and has also established that TNF is a potent activator of latent NF-kappaB activity in cells (reviewed in (9) and (10) ). A significant advance in understanding the mechanism of NF-kappaB activation by TNFalpha has resulted from the isolation of proteins that interact with the cytoplasmic domains of TNF-R1 and TNF-R2 and mimic some of the actions of TNFalpha(11, 12) .

Consistent with the observation that the primary amino acid sequence of the intracellular domains of TNF-R1 and TNF-R2 displays no detectable sequence similarity, distinct proteins have been found to interact with the cytoplasmic region of the two receptors. In the case of TNF-R2, two related proteins, TRAF-1 and TRAF-2, form a heteromeric complex with the cytoplasmic domains of the receptor, and overexpression of TRAF-2 has been shown to activate NF-kappaB(11, 13) . The TRAF proteins define a new family of signaling molecules that includes CD40bp or CRAF-1, a protein that interacts with the cytoplasmic domain of another TNF receptor family member CD40(14, 15) .

Structure-function analysis of signaling by TNF-R1 has demonstrated that an 80-amino acid region within the cytoplasmic domain is required for initiation of programmed cell death and NF-kappaB activation (16) . This region, designated the death domain, is 28% identical over a stretch of 65 amino acids to an intracellular region of the FAS antigen(17) , another member of the TNF receptor family that can activate programmed cell death. Insight into signal transduction by TNF-R1 has resulted from identification of a 34-kDa protein, designated TRADD, in a yeast two-hybrid screen for proteins interacting with the intracellular domain of TNF-R1(12) . TRADD interacts with the death domain of TNF-R1, and TRADD overexpression causes NF-kappaB activation and initiates programmed cell death, implicating it as a signaling molecule downstream of the receptor. Two additional TNF-R1 interacting proteins have been isolated using a two-hybrid screen. These two proteins interact with a membrane-proximal region of the receptor that does not include the death domain, and their role in TNF-R1 signaling is unclear(18) .

Mutational studies of TRADD have demonstrated that 111 amino acids within the carboxyl-terminal half of the molecule are necessary and sufficient for self-association and binding to TNF-R1 as well as for inducing NF-kappaB activation and cell death(12) . The functionally important part of TRADD appears to harbor a death domain, since a 68-amino acid stretch within this region shows 32% sequence identity with the TNF-R1 death domain. The death domain of TRADD is more related to that of TNF-R1 than FAS, and it does not interact with the death domain in FAS. Regions homologous to the death domains of TNF-R1 and FAS have been found in two other proteins including MORT1/FADD and RIP (19, 20, 21) . Both of these proteins interact via their death homology regions with the death domain of FAS but only weakly with TNF-R1, and both induce apoptosis when overexpressed in mammalian cells. With FADD, the region that interacts with FAS is separable from the one that activates the cell death pathway. The carboxyl-terminal part of MORT1/FADD is similar in primary amino acid sequence to the FAS death domain and is capable of direct interaction with it. However, expression of the amino-terminal 117 amino acids, lacking most of the death homology region of MORT-1/FADD, triggers cell death(20) . First identified as a protein-protein interaction motif employed by members of the TNF-R1 family involved in signaling cell death and NF-kappaB activation, the death domains may be present in other proteins with diverse functions(22, 23) . The rules governing interactions of the different death domains are unclear. Likewise it is not known how certain death domains signal cell death when overexpressed, whereas others do not.

The TRADD death domain performs multiple functions including self-association, binding to TNF-R1, activation of NF-kappaB, and induction of cell death(12) . To determine whether these various activities specified by TRADD map to distinct regions within the death domain and to gain a better understanding of TRADD's role in signal transduction by TNF-R1 we have performed an alanine scan mutagenesis of TRADD's death domain. Alanine substitution mutants have been surveyed for their capacity to oligomerize and interact with TNF-R1 in binding assays and to activate NF-kappaB and induce cell death in transfection assays. The entire death domain appears to be involved in self-association of TRADD and binding to TNF-R1. It is shown that the regions of the death domain mediating NF-kappaB activation and induction of cell death overlap. However, one mutant was identified that kills cells but does not activate NF-kappaB. Furthermore, a TRADD mutant with alanines in positions 296-299 behaves as a dominant negative variant capable of preventing induction of a NF-kappaB reporter plasmid by TNFalpha.


MATERIALS AND METHODS

Cell Culture and Transfections

The cell lines 293 and HtTA-1 (a HeLa derivative) were propagated as described(12) . For NF-kappaB activation assays, 293 cells were transfected with 0.2 µg of E-selectin luciferase, 1 µg of pRK vector expressing TRADD mutants, 0.1 µg of cytomegalovirus beta-galactosidase, and 1.2 µg of pUC118 DNA by the calcium phosphate precipitation method as described(12) . Thirty hours after transfection cells were either stimulated with 20 ng/ml recombinant human TNFalpha (R& Systems) or left unstimulated. Approximately 12 h later cells were harvested and assayed for luciferase. beta-Galactosidase activity was measured with a chemiluminescent assay as follows. Cell extracts were incubated with 100 µl of a 1:100 dilution of Galacton (Tropix, Inc.) in phosphate-buffered saline with 1 mM MgCl(2) for 1 h. Samples were read on the luminometer as for the luciferase assay after addition of 60 µl of Emerald (Tropix Inc.) diluted in phosphate-buffered saline with 0.2 N NaOH. beta-Galactosidase activity was used to normalize luciferase activity. All transfections were performed in duplicate, and the data shown are the average of at least two independent transfections. Standard error for all measurements was <20%. For cell killing assays, HtTA-1 cells were transfected similar to 293 cells except that the E-selectin luciferase DNA was not included. Cells were stained for beta-galactosidase expression 48 h after transfection, and the percentage of blue cells exhibiting a flat adherent morphology typical of live cells was determined. Blue cells that were rounded and loosely attached to the substratum were considered to be dead.

Plasmids

The NF-kappaB-dependent reporter plasmid E-selectin luciferase has -730 to +52 of the E-selectin promoter linked to luciferase coding sequences, and TNF-induced expression of this plasmid has been shown to require NF-kappaB binding sites(24) . The plasmid pTRADD-(aa196-312) was constructed from the cytomegalovirus immediate early promoter-enhancer expression plasmid pRK5(25) . pTRADD-(aa196-312) encodes human TRADD starting at amino acid 196 with a myc epitope encoding MASMEQKLISEEDLGIP at the amino terminus. The alanine substitution mutants were generated by polymerase chain reaction. To facilitate mutagenesis, three restriction sites unique to TRADD-(aa196-312) were introduced, which did not alter the encoded polypeptide sequence. To construct the mutants a primer with the desired nucleotide changes and overlapping an unique restriction site was used in combination with a primer flanking the TRADD sequences to amplify a portion of TRADD. The amplified fragment with the nucleotide changes was digested with appropriate restriction sites and substituted for the wild type sequence in TRADD-(aa196-312). Mutants are named with numbers corresponding to the amino acids that have been substituted. All mutants were confirmed by DNA sequencing. pTRADD-(aa25-312) and pTRADD-(aa112-312) were constructed from pTRADD-(aa1-312) by polymerase chain reaction-based mutagenesis. 296FL, 296L and 296S were constructed, respectively, from TRADD-(aa1-312), TRADD-(aa25-312), and pTRADD-(aa112-312) by substituting the aa296-299 mutation for the wild type sequence. The expression vector encoding TNF-R1 sequences has been described(16) . The flag epitope used encodes the sequence MDYKDDDDK and was introduced at the amino-terminal end of TRADD-(aa1-312).

In Vitro Binding and Co-immunoprecipitation Assays

Glutathione S-transferase (GST) fusion with TNF-R1 intracellular domain has been described (12) and contains amino acids 214-426 of human TNF-R1 fused to GST in a pGEX vector (Pharmacia Biotech Inc.). GST-TRADD is a similar fusion and has amino acids 9-312 of human TRADD(12) . Binding assays were done with in vitro translated mutants and GST fusion proteins as described (12) after normalizing for the amount of protein synthesized in vitro. Binding of mutants was quantitated with a Phosphoimager (Fuji Inc.) and is expressed relative to that of TRADD-(aa196-312). Co-immunoprecipitation assays were done as described(12) . 293 cells (3 times 10^6/10-cm dish) were transfected with 10 µg of each DNA. Cells were harvested 24 h later, and lysates were used for immunoprecipitation with the indicated antibodies. Protein immunoblots were developed with ECL reagents (Amersham Corp.).


RESULTS AND DISCUSSION

In Vitro Binding Properties of TRADD Death Domain Mutants

A derivative of TRADD extending from amino acids 195 to 312 retains all the activities associated with full-length TRADD including multimerization, binding to TNF-R1, and induction of NF-kappaB and of programmed cell death(12) . We focused on amino acids 196-305 for mutagenesis, since the carboxyl-terminal seven amino acids are dispensable for TRADD function(12) . A series of 33 TRADD death domain mutants was generated in which groups of three or four contiguous amino acids were simultaneously changed to alanine (Fig. 1A). Alanine was chosen as the substituent amino acid, since changes to alanine eliminates the contribution from the side chain of the replaced amino acid with minimal alteration of the overall protein structure.


Figure 1: In vitro binding assays with TRADD death domain mutants. A, sequence of TRADD death domain from amino acid 196 to 305(12) . The amino acids substituted to alanine in the individual mutants are underlined. Numbers above the sequence correspond to the first amino acid changed in each mutant. B, percent binding of each mutant to GST-TRADD (top panel) and GST-TNF-R1-(aa214-426) (bottom panel) is shown as a bar graph. Binding was determined by precipitation of in vitro synthesized S-labeled TRADD mutant proteins with the GST fusion proteins coupled to glutathione-Sepharose. The precipitated proteins were resolved on a SDS-polyacrylamide gel, and the labeled protein brought down was quantitated with a Phosphoimager. The amount of in vitro translated TRADD-(aa196-312) bound to each wild type GST fusion protein was considered 100%. The numbers below the bottom panel correspond to amino acid positions in TRADD.



We first examined TRADD mutants for their ability to self-associate or bind TNF-R1. In vitro synthesized TRADD associates specifically with either TRADD or the intracellular domain of TNF-R1 fused to GST. The GST fusions are attached to glutathione-agarose beads, which facilitates separation of the TRADD bound to the fusion protein from unbound TRADD(12) . This in vitro biochemical assay was used to compare the binding of TRADD-(aa196-312) and various substitution mutants to GST-TRADD and GST-TNF-R1. Mutations resulting in reduced binding to GST-TRADD and GST-TNF-R1 were distributed over the entire death domain, indicating that there were no subregions dedicated exclusively to TRADD multimerization or TNF-R1 binding (Fig. 1B). TRADD self-association may be essential for interaction with TNF-R1, since all mutations that reduced binding to GST-TRADD also compromised GST-TNF-R1 binding. Consistent with this interpretation, alanine substitutions at more positions affected binding to GST-TNF-R1 than to GST-TRADD. The TRADD-TNF-R1 interaction detected here may therefore reflect the binding of an oligomerized TRADD molecule to TNF-R1, and the interface involved in TRADD-TNF-R1 contact is likely to be different from that involved in TRADD-TRADD contact.

Activation of NF-kappaB-dependent Reporter Gene Expression

Expression of TRADD in 293 cells activates latent, cytoplasmic NF-kappaB to generate nuclear NF-kappaB DNA binding activity and results in activation of expression from a NF-kappaB-dependent reporter gene(12) . To assess the potential of TRADD death domain mutants to activate NF-kappaB, expression plasmids encoding TRADD-(aa196-312) and various mutants were transfected into 293 cells along with a NF-kappaB-dependent reporter plasmid, E-selectin luciferase. Luciferase activity was then determined from extracts of cells that were either stimulated with TNF for 12 h or left unstimulated. Expression of all mutants was confirmed by Western blot analysis with an antibody directed against the myc epitope tag present at the amino terminus of the proteins. (^2)As was observed with binding of the mutants to GST-TNF-R1 and GST-TRADD, mutations eliminating the capacity of the TRADD death domain to activate NF-kappaB were not restricted to any one part of the death domain (Fig. 2A). The NF-kappaB activation function is therefore dependent upon integrity of much of the 100-amino acid region of TRADD. Five mutations (aa219-221, aa222-225, aa245-248, aa249-251, and aa269-271) that showed little or no detectable binding to GST-TNF-R1 in the in vitro binding assay were capable of inducing the NF-kappaB-dependent reporter to a similar extent as intact TRADD-(aa196-312) (Fig. 2A). If the failure of these mutants to interact with TNF-R1 in vitro reflects a similar lack of association with the receptor in cells, then this finding implies that the TRADD death domain can initiate NF-kappaB activation independent of TNF-R1 when it is overexpressed in cells. Alternately, the large amount of TRADD protein produced in cells under conditions of transient transfection may result in a weak binding to the receptor sufficient to trigger NF-kappaB activation. In either case, there is no correlation between the extent of NF-kappaB activation and binding of TRADD mutants to TNF-R1 in vitro. It is therefore highly unlikely that induction of NF-kappaB by the overexpressed TRADD death domain is a mere consequence of it functioning as an intracellular ligand and clustering the receptor to stimulate other effector molecules.


Figure 2: Biological activity of TRADD death domain mutants. A, bar graph displaying capacity of TRADD death domain mutants to activate expression of a NF-kappaB-dependent reporter gene. 293 cells transfected with expression vectors for the mutants and an E-selectin luciferase plasmid (24) were either unstimulated or stimulated with TNFalpha for approximately 12 h before harvest. Cells were assayed for luciferase activity as detailed under ``Materials and Methods.'' Activation observed with TRADD-(aa196-312) in unstimulated cells was set at 100%, and activation observed with the mutants is expressed relative to it. The numbers below the graph correspond to amino acid positions in TRADD. The upper panel presents the activity observed in unstimulated cells and the lower panel the activity seen in cells stimulated with TNFalpha. The dashed line in the lower panel indicates the base-line activity observed in cells co-transfected with the E-selectin reporter and an expression vector lacking TRADD sequences and stimulated with TNF. TNFalpha enhanced expression of this reporter gene by approximately 20-fold. B, cell killing activity of TRADD death domain mutants presented as a bar graph. HtTA cells were co-transfected with the various TRADD mutants and a beta-galactosidase expression vector. Cells were stained for beta-galactosidase, and the percentage of blue cells that were flat and adherent were counted microscopically and considered live. Cell killing observed with TRADD-(aa196-312) was set at 100%, and killing activity of the mutants is expressed relative to it. A background killing (10%) that was observed when an expression vector lacking TRADD was transfected has been subtracted. The data presented are that observed with unstimulated cells. Similar results were observed when the transfected cells were stimulated with TNF for approximately 12 h.



Mutant aa296-299 showed detectable interaction in vitro with both GST-TNF-R1 and GST-TRADD yet did not activate NF-kappaB in transiently transfected cells (Fig. 1B and Fig. 2A). Moreover, expression of the E-selectin luciferase reporter was consistently lower when cells transfected with this mutant were stimulated with TNF than in cells transfected with a control vector lacking TRADD sequences. These observations indicate that the mutant might interfere with TNF-induced NF-kappaB activation, perhaps by preventing endogenous TRADD and/or TNF-R1 from interacting with downstream effector molecules. The aa296-299 change was reconstructed in a TRADD protein starting at amino acid 25 to confirm and extend the findings with the mutant in the death domain background. Both TRADD-(aa196-312) and TRADD-(aa25-312) with the aa296-299 substitution potently prevented induction of the NF-kappaB reporter gene by TNF in a dose-dependent manner without significantly affecting induction by IL-1 (Fig. 3A). As a control, another mutant that does not activate NF-kappaB (aa210) was tested for its capacity to prevent induction of the NF-kappaB reporter plasmid by TNF. Unlike mutant aa296-299, mutant aa210 failed to block TNF-induced reporter gene expression.^2 Taken together, these findings provide evidence that changing amino acids 296-299 to alanine results in a dominant negative TRADD mutant. To demonstrate that TRADD with the aa296-299 substitution could associate with native TRADD and interact with TNF-R1 in cells, a co-immunoprecipitation experiment was performed (Fig. 3C). 293 cells were co-transfected with expression vectors for myc epitope-tagged TRADD having the wild type sequence or alanine substitution at aa296-299 and expression vectors for either TNF-R1 or flag epitope-tagged TRADD. TNF-R1 and flag-TRADD were immunoprecipitated from the transfected cells, and the myc-tagged TRADD brought down with these proteins was determined with a Western blot (Fig. 3C). Immunoprecipitation with irrelevant antibodies confirmed that co-precipitation of myc-tagged TRADDs was specific for the anti-TNF-R1 and anti-Flag antibodies.^2 Alanine substitutions at 296-299 did not affect association with TNF-R1 or TRADD. Taken together the results of the transfection assays confirm the involvement of TRADD in the NF-kappaB activation pathway and furthermore demonstrate an obligate role for TRADD function in TNF-initiated NF-kappaB activation.


Figure 3: Effect of mutant aa296-299 on NF-kappaB activation. A, mutant aa296-299 blocks NF-kappaB activation induced by TNF but not IL-1. 293 cells were co-transfected with the NF-kappaB-dependent reporter plasmid and varying amounts of TRADD-(aa196-312) with alanines at amino acids 296-299 (296S) or TRADD-(25-312) with alanines at amino acids 296-299 (296L) as indicated. For each data point the amount of expression plasmid was made up to 1 µg by addition of expression vector lacking TRADD sequences. Forty hours after transfection, cells were stimulated with TNFalpha or IL-1beta for 8 h, and the cells were then harvested and assayed for luciferase activity. The -fold increase in reporter gene expression observed when 1 µg of empty expression vector was co-transfected is set at 100 for both TNFalpha and IL-1beta treatment. The actual increase observed was 20.5-fold for TNF and 8.5-fold for IL-1beta. B, activation of NF-kappaB-dependent reporter gene expression by amino-terminal truncations of TRADD and TRADD with the aa296-299 substitution. The E-selectin luciferase reporter was co-transfected with full-length (aa1-312), truncated (aa25-312), or just the death domain (aa196-312) of TRADD with the native sequence or with alanines at aa296-299 (296FL, 296L, and 296S). Luciferase activity was determined in unstimulated (-TNF) or cells stimulated with TNF for 8 h (+TNF). The numbers given are relative to the luciferase activity observed for cells transfected with the empty expression vector and left unstimulated. The asterisks denote the substitution of alanines at amino acids 296-299. C, co-immunoprecipitation of TRADD having the aa296-299 substitution with TNF-R1 and native TRADD. Expression vectors lacking TRADD sequences(-) or encoding myc epitope-tagged TRADD-(aa112-312) with the wild type sequence (WT) or with alanines at aa296-299 (296) were co-transfected into 293 cells along with expression vectors encoding TNF-R1 (lanes 1-3) and native TRADD with a flag tag (lanes 4-6). Cell lysates were immunoprecipitated with a polyclonal rabbit antiserum to TNF-R1 (lanes 1-3) or anti-flag monoclonal antibody (lanes 4-6). Immunoprecipitates were resolved on a SDS-polyacrylamide gel, and the myc epitope-tagged TRADD brought down was detected in a protein immunoblot with an anti-myc monoclonal antibody.



Analysis of NF-kappaB activation by aa296-299 mutants provided an additional insight into TRADD function. A full-length TRADD protein with the aa296-299 substitution (296FL) reproducibly enhanced expression from a co-transfected NF-kappaB reporter plasmid to a small extent, approximately 6-fold compared with 37-fold with native TRADD, even though this same mutation inactivated the death domain (Fig. 3B). Similar results were obtained with the mutation aa300-302. In the context of the death domain alone substituting amino acids 300-302 with alanine inactivated TRADD; however, full-length TRADD with the same substitutions showed low levels of NF-kappaB-inducing activity.^2 Removal of 24 amino acids from the amino terminus of 296FL abolishes the residual NF-kappaB inducing activity and unmasks the dominant negative effect of this mutation on TNF-induced NF-kappaB activation. This supplementary role of the amino terminus is most readily observed in mutants that compromise the activity of the death domain. However, amino-terminal deletions of wild type TRADD also show a 2-4-fold reduction in NF-kappaB activation confirming the importance of this region (Fig. 3B). All of these observations suggest that the amino-terminal half of TRADD contributes to NF-kappaB activation by the death domain. Additional experiments are needed to determine whether the amino-terminal sequences facilitate NF-kappaB activation by stabilizing the interaction of effector proteins with the death domain or by being a site for interaction of additional factors.

Induction of Cell Death by TRADD Mutants

TRADD overexpression in cells induces apoptosis(12) . We used a co-transfection assay (26) with a beta-galactosidase expression vector to monitor the apoptotic effect of TRADD. HtTA cells were transfected with the various TRADD mutants and a plasmid encoding beta-galactosidase, and 40 h after transfection beta-galactosidase-expressing cells were visualized by staining. The percentage of stained cells that exhibited a flat adherent morphology characteristic of live cells was determined. As shown in Fig. 2, there was a good correlation between the capacity of mutants to induce cell killing and activate NF-kappaB. With one exception all mutants that activated NF-kappaB-dependent reporter expression induced cell death, and all mutants that failed to activate expression did not kill. Mutant aa241-244 consistently failed to activate expression of the NF-kappaB-dependent reporter (less than 1.5-fold activation) but was as effective at inducing cell death as the TRADD death domain. The cowpox virus gene product, CrmA, which inhibits TNF- and TRADD-induced cell death(12, 27) , also prevented killing by the mutant aa241-244,^2 suggesting that similar cell killing pathways were being used by the mutant as by TRADD. The demonstration that cell killing and NF-kappaB-inducing activity of TRADD are separable functions implies that the two TNFalpha-activated pathways are distinct and suggests that they may bifurcate at TRADD.

In summary, our mutational analyses indicate that the TRADD death domain cannot be subdivided into discrete regions that are individually responsible for the different functions of TRADD. It appears therefore that this domain is not composed of independent subdomains that are individually dedicated to different functions of TRADD such as oligomerization, TNF-R1 binding, NF-kappaB activation, and cell killing but rather that the TRADD death domain is a multifunctional unit performing all of these functions. Further insight into a structure-function relationship will require knowledge of the three-dimensional structure of the TRADD death domain. The protein interfaces involved in multimerization of TRADD and binding to TNF-R1 appear distinct but overlapping. TRADD self-association is likely to be a prerequisite for binding to TNF-R1 suggesting that a multimer of TRADD interacts with TNF-R1. TNFalpha is thought to induce receptor clustering on binding to TNF-R1, and it has been proposed that TRADD may preferentially bind to aggregated TNF-R1(12) . It is possible then that interaction between TRADD and TNF-R1 involves binding of two multimerized death domains, and, in general, self-association of a death domain is different from the interaction of death domains from two different proteins.

The amino acid residues involved in signaling NF-kappaB activation and apoptosis are largely coincident, but these two activities are separable. The tight link between NF-kappaB activation and induction of cell death may reflect the interaction with TRADD of distinct but related proteins to mediate the two functions or alternately the existence of a single complex that can execute the signals required to activate both pathways. Most importantly, the mutagenesis has identified a dominant negative mutant, which indicates that the TNF-induced NF-kappaB activation pathway proceeds through TRADD. Finally, the TRADD mutants described here should prove useful in deciphering the role of any new TRADD-interacting proteins that emerge from future studies.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

(^1)
The abbreviations used are: TNF, tumor necrosis factor; TNF-R, TNF receptor; aa, amino acids; GST, glutathione S-transferase; IL, interleukin.

(^2)
A. Park and V. R. Baichwal, unpublished observations.


ACKNOWLEDGEMENTS

We thank Keith Williamson for DNA sequencing and Hailing Hsu for helpful discussions. We also thank David V. Goeddel, Kelly LaMarco, and Steve McKnight for comments on the manuscript.


REFERENCES

  1. Goeddel, D. V., Aggarwal, B. B., Gray, P. W., Leung, D. W., Nedwin, G. E., Palladino, M. A., Patton, J. S., Pennica, D., Shepard, H. M., Sugarman, B. J., and Wong, G. H. W. (1986) Cold Spring Harbor Symp. Quant. Biol. 51, 597-609 [Medline] [Order article via Infotrieve]
  2. Fiers, W. (1991) FEBS Lett. 285, 199-212 [CrossRef][Medline] [Order article via Infotrieve]
  3. Beutler, B., and Cerami, A. (1988) Annu. Rev. Biochem. 57, 505-518 [CrossRef][Medline] [Order article via Infotrieve]
  4. Tartaglia, L. A., and Goeddel, D. V. (1992) Immunol. Today 13, 151-153 [CrossRef][Medline] [Order article via Infotrieve]
  5. Vandenabeele, P., Declercq, W., Beyaert, R., and Fiers, W. (1995) Trends Cell Biol. 5, 392-399 [CrossRef]
  6. Tartaglia, L. A., and Goeddel, D. V. (1992) J. Biol. Chem. 267, 4304-4307 [Abstract/Free Full Text]
  7. Boldin, M. P., Mett, I. L., Varfolomeev, E. E., Chumakov, I., Shemer-Avni, Y., Camoni, J. H., and Wallach, D. (1995) J. Biol. Chem. 270, 387-391 [Abstract/Free Full Text]
  8. Heller, R. A., and Kronke, M. (1994) J. Cell Biol. 126, 5-9 [Medline] [Order article via Infotrieve]
  9. Collins, T., Read, M. A., Neish, A. S., Whitely, M. Z., Thanos, D., and Maniatis, T. (1995) FASEB J. 9, 899-909 [Abstract/Free Full Text]
  10. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 12, 141-179 [CrossRef][Medline] [Order article via Infotrieve]
  11. Rothe, M., Wong, S. C., Henzel, W. J., and Goeddel, D. V. (1994) Cell 78, 681-692 [Medline] [Order article via Infotrieve]
  12. Hsu, H., Xiong, J., and Goeddel, D. V. (1995) Cell 81, 495-504 [Medline] [Order article via Infotrieve]
  13. Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V. (1995) Science 269, 1424-1427 [Medline] [Order article via Infotrieve]
  14. Hu, H. M., O'Rourke, K., Boguski, M. S., and Dixit, V. M. (1994) J. Biol. Chem. 269, 30069-30072 [Abstract/Free Full Text]
  15. Cheng, G., Cleary, A. M., Ye, Z.-S., Hong, D., Lederman, S., and Baltimore, D. (1995) Science 267, 1494-1498 [Medline] [Order article via Infotrieve]
  16. Tartaglia, L. A., Ayres, T. M., Wong, G. H. W., and Goeddel, D. V. (1993) Cell 74, 845-853 [Medline] [Order article via Infotrieve]
  17. Itoh, N., and Nagata, S. (1993) J. Biol. Chem. 268, 10932-10937 [Abstract/Free Full Text]
  18. Song, H. Y., Dunbar, J. D., Zhang, Y. X., Guo, D., and Donner, D. B. (1995) J. Biol. Chem. 270, 3574-3581 [Abstract/Free Full Text]
  19. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. (1995) J. Biol. Chem. 270, 7795-7798 [Abstract/Free Full Text]
  20. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995) Cell 81, 505-512 [Medline] [Order article via Infotrieve]
  21. Stanger, B. Z., Leder, P., Lee, T.-H., Kim, E., and Seed, B. (1995) Cell 81, 513-523 [Medline] [Order article via Infotrieve]
  22. Cleveland, J. L., and Ihle, J. N. (1995) Cell 81, 479-482 [Medline] [Order article via Infotrieve]
  23. Feinstein, E., Kimchi, A., Wallach, D., Boldin, M., and Varfolomeev, E. (1995) Trends Biochem. Sci. 20, 342-344 [CrossRef][Medline] [Order article via Infotrieve]
  24. Schindler, U., and Baichwal, V. R. (1994) Mol. Cell. Biol. 14, 5820-5831 [Abstract]
  25. Schall, T. J., Lewis, M., Koller, K. J., Lee, A., Rice, G. C., Wong, G. H. W., Gatanaga, T., Granger, G. A., Lentz, R., Raab, H., Kohr, W. J., and Goeddel, D. V. (1990) Cell 61, 361-370 [Medline] [Order article via Infotrieve]
  26. Kumar, S., Kinoshita, M., Noda, M., Copeland, N. G., and Jenkins, N. A. (1994) Genes & Dev. 8, 1613-1626
  27. Tewari, M., and Dixit, V. M. (1995) J. Biol. Chem. 270, 3255-3260 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.